RS52424B - COMBINATION OF BETA-INTERFERONES AND CLADRIBIN REGULATED FOR THE TREATMENT OF MULTIPLE SCLEROSIS - Google Patents

COMBINATION OF BETA-INTERFERONES AND CLADRIBIN REGULATED FOR THE TREATMENT OF MULTIPLE SCLEROSIS

Info

Publication number
RS52424B
RS52424B RS20120252A RSP20120252A RS52424B RS 52424 B RS52424 B RS 52424B RS 20120252 A RS20120252 A RS 20120252A RS P20120252 A RSP20120252 A RS P20120252A RS 52424 B RS52424 B RS 52424B
Authority
RS
Serbia
Prior art keywords
multiple sclerosis
interferon
beta
combination
treating multiple
Prior art date
Application number
RS20120252A
Other languages
English (en)
Serbian (sr)
Inventor
Maria Lopez-Bresnahan
Nazih Ammoury
H. James Brentzel Jr
Original Assignee
Merck Serono Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Serono Sa filed Critical Merck Serono Sa
Priority claimed from PCT/EP2007/055013 external-priority patent/WO2007135172A2/en
Publication of RS52424B publication Critical patent/RS52424B/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/215—IFN-beta
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
RS20120252A 2006-05-24 2007-05-23 COMBINATION OF BETA-INTERFERONES AND CLADRIBIN REGULATED FOR THE TREATMENT OF MULTIPLE SCLEROSIS RS52424B (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP06114537 2006-05-24
US84547006P 2006-09-18 2006-09-18
PCT/EP2007/055013 WO2007135172A2 (en) 2006-05-24 2007-05-23 Cladribine regimen for treating multiple sclerosis

Publications (1)

Publication Number Publication Date
RS52424B true RS52424B (en) 2013-02-28

Family

ID=37395884

Family Applications (1)

Application Number Title Priority Date Filing Date
RS20120252A RS52424B (en) 2006-05-24 2007-05-23 COMBINATION OF BETA-INTERFERONES AND CLADRIBIN REGULATED FOR THE TREATMENT OF MULTIPLE SCLEROSIS

Country Status (12)

Country Link
CN (1) CN101500598A (es)
AT (1) ATE555804T1 (es)
BR (1) BRPI0710326A2 (es)
DK (1) DK2026832T3 (es)
EC (1) ECSP088997A (es)
ES (1) ES2384399T3 (es)
MY (1) MY149042A (es)
NZ (1) NZ572680A (es)
PT (1) PT2026832E (es)
RS (1) RS52424B (es)
SI (1) SI2026832T1 (es)
UA (1) UA96941C2 (es)

Also Published As

Publication number Publication date
CN101500598A (zh) 2009-08-05
UA96941C2 (ru) 2011-12-26
PT2026832E (pt) 2012-06-01
NZ572680A (en) 2011-11-25
BRPI0710326A2 (pt) 2011-08-09
DK2026832T3 (da) 2012-06-25
SI2026832T1 (sl) 2012-07-31
ECSP088997A (es) 2009-01-30
MY149042A (en) 2013-07-15
ATE555804T1 (de) 2012-05-15
ES2384399T3 (es) 2012-07-04

Similar Documents

Publication Publication Date Title
WO2007135172A3 (en) Cladribine regimen for treating multiple sclerosis
PH12014502847A1 (en) Combination treatment (eg with abt-072-333) of daas for use in treating hcv
PH12014502848A1 (en) Methods for treating hcv comprising at least two direct acting antiviral agent, ribavirin but not interferon
ZA200807879B (en) Use of bifidobacterium longum for the prevention and treatment of inflammation
MY162067A (en) Combination therapy for treatment of patients with neurological disorders and cerebral infarction
HK1142270A1 (en) Silibinin component for the treatment of hepatitis
PH12013501790A1 (en) Uses of dpp~iv inhibitors
UA106756C2 (uk) Генетичні маркери, асоційовані з відповіддю на інтерферон-альфа
TN2011000176A1 (en) Treatment for diabetes in patients with insufficient glycemic control despite therapy with an oral or non-oral antidiabetic drug
MX2008013304A (es) Compuestos de peptido 1 tipo glucagon.
TW200630105A (en) Herbal composition PHY906 and its use in chemotherapy
MX2014002555A (es) Una composicion farmacéutica para tratar cáncer, que comprende un conjugado de interferón alfa.
WO2012063134A3 (en) Cardiac glycoside analogs in combination with emodin for cancer therapy
NZ705124A (en) Interferon-beta for use as monotherapy or in combination with other cancer therapies
MX2009003532A (es) Tratamiento de hiperbilirrubinemia infantil utilizando bajas dosis de estansoporfina.
SI2026832T1 (sl) Kombinacija interferona beta in kladribinskega režima za zdravljenje multiple skleroze
Fukumoto et al. New hope for Nutlin-3a therapy for pulmonary arterial hypertension
UA103907C2 (ru) Терапевтический режим лечения гепатита, который включает пег-интерферон, рибавирин и vx-950
UA41629U (ru) Способ лечения хронической токсоплазмозной инфекции
UA66404U (ru) Способ профилактики и лечения остеопороза у беременных с перинатальным инфицированием
MY174803A (en) Treatment for diabetes in patients with insufficient glycemic control despite therapy with an oral or non-oral antidiabetic drug
UA99163C2 (ru) Способ дозирования инъекционной формы палиперидона пальмитата продолжительного действия
SG146498A1 (en) Compositions for treatment of patients with neurological disorders and cerebral infarction
UA50803U (ru) Способ лечения острых инфекционных вирусных заболеваний у больных с хронической патологией органов пищеварения